DURHAM, N.C., July 8, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the presentation of three abstracts on its investigational broad-spectrum antiviral, brincidofovir (BCV, CMX001), at the 2014 World Transplant Congress (WTC) being held July 26-31, 2014 at the Moscone West Convention Center in San Francisco.
The company is currently enrolling adult hematopoietic cell transplant (HCT) recipients in the brincidofovir Phase 3 SUPPRESS trial for the prevention of cytomegalovirus (CMV) infection, and is enrolling immunocompromised patients in the pilot portion of a brincidofovir Phase 3 trial for the treatment of disseminated adenovirus (AdV) infection. The data being presented at WTC highlight brincidofovir's antiviral activity and favorable safety profile in HCT and solid organ transplant recipients who were treated with brincidofovir for viral infections, such as CMV, AdV, BK virus, and Epstein-Barr virus.
Chimerix Presentations at the World Transplant Congress
Brincidofovir (CMX001) for the Treatment of Serious or Life-Threatening Double-stranded DNA Virus Infections in Patients Receiving Liver Transplant as Part of Multiorgan Transplantation
Presenter: Diana Florescu, MD, University of Nebraska Medical Center
Date: Sunday, July 27 at 6:30 pm PDT
Session: Poster Late Breaker 1 (Publication #A2979)
Switch from Existing Antivirals to Brincidofovir Leads to Improving Renal Function
Presenter: Marion Morrison, MD, Chimerix, Inc.
Date: Tuesday, July 29 from 4:00 - 5:30 pm PDT
Session: Infectious Complications Post Kidney Transplantation (Publication #1472)
Brincidofovir (CMX001) Experience in Renal Transplant Patients for Treatment of Refractory CMV Infection
Presenter: Kathleen Mullane, DO, PharmD, University of Chicago
Date: Wednesday, July 30 at 5:30 pm PDT
Session: Infectious Complications - Post Transplantation (Publication #D2364)
About Brincidofovir (CMX001)
Chimerix's lead product candidate, brincidofovir, is an oral nucleotide analog that has shown broad-spectrum in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpes virus family and AdV. Brincidofovir has shown no evidence of kidney or bone marrow toxicity in nearly 900 patients exposed to date. Building on the positive Phase 2 results in CMV prevention, Chimerix initiated the Phase 3 SUPPRESS trial in 2013. If positive, data from SUPPRESS will support Chimerix's initial regulatory submission for brincidofovir for the prevention of CMV infection in adult HCT recipients. Chimerix recently initiated a Phase 3 trial in AdV, an often-fatal viral infection with no approved treatment; enrollment is ongoing for the pilot portion of that trial. Chimerix is also working with Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received Fast Track designation from the FDA for CMV, AdV, and smallpox.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary technology has given rise to brincidofovir (CMX001), a clinical-stage nucleotide analog lipid-conjugate, which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Chimerix is currently enrolling SUPPRESS, a Phase 3 study of brincidofovir for the prevention of cytomegalovirus in HCT recipients. In addition Chimerix is enrolling the pilot portion of a Phase 3 study of brincidofovir for treatment of disseminated adenovirus infection. Chimerix is working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. For further information, please visit Chimerix's website, www.chimerix.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Chimerix's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q, its most recently filed Current Reports on Form 8-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Chimerix undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: CHIMERIX CONTACT:
Joseph T. Schepers
Executive Director, Investor Relations and
Source: Chimerix, Inc.